CorMedix CRMD 深 沪
等待开盘 11-18 09:30:00 美东时间
9.98
-1.260
-11.21%
华盛通- 最 高11.185
- 今 开11.17
- 成交量 557.89万股
- 最 低 9.81
- 昨 收 11.24
- 总市值 7.79亿
- 52周最高 17.43
- 市盈率 静 --
- 换手率 7.15%
- 52周最低 5.60
- 委 比 -77.41%
- 总股本 7805.87万
- 历史最高 52.00
- 量 比 1.17
- 振 幅 12.23%
- 历史最低 0.73
- 每 手 1
- 风险率 1.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
11-13 09:58
D. Boral Capital Maintains Buy on Cormedix, Maintains $14 Price Target
D. Boral Capital analyst Jason Kolbert maintains Cormedix (NASDAQ:CRMD) with a Buy and maintains $14 price target.
11-13 03:09
CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations
CorMedix posts strong Q3 results with $104 million in revenue, higher DefenCath sales, and raises 2025 guidance following Melinta integration progress.
11-13 00:49
Pharming Group Posts Upbeat Q3 Results, Joins On Holding, BigBear.ai Holdings And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index gaining more than 300 points o...
11-13 00:19
Cormedix Sees Q4 Sales $115.000M-$135.000M vs $118.847M Est
Cormedix (NASDAQ:CRMD) sees Q4 sales of $115.000 million-$135.000 million vs $118.847 million analyst estimate.
11-12 20:40
Cormedix Q3 EPS $1.26 Beats $0.63 Estimate, Sales $104.270M Beat $86.023M Estimate
Cormedix (NASDAQ:CRMD) reported quarterly earnings of $1.26 per share which beat the analyst consensus estimate of $0.63 by 100.64 percent. This is a 2620 percent increase over losses of $(0.05) per share from the same
11-12 20:32
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
11-12 19:11
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025
<p>CorMedix Inc. announced it will report third-quarter 2025 financial results before the market opens on November 12, 2025, followed by a corporate update conference call at 8:30am ET. Registered participants can join via dial-in numbers or webcast. The company, specializing in therapeutic products for life-threatening diseases, recently acquired Melinta Therapeutics LLC, adding a portfolio of anti-infective products to its offerings. CorMedix i...
10-31 12:30
CorMedix Says DefenCath Receives Innovative Technology Designation From Vizient
CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that DefenCath has received an
10-23 20:32
